A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain

Franco De Conno, Carla Ripamonti, Alberto Sbanotto, Lucilla Barletta, Ernesto Zecca, Cinzia Martini, Vittorio Ventafridda

Research output: Contribution to journalArticle

Abstract

The authors report a prospective study on 944 cancer pain patients treated with one of the following opioids: codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine. Level of analgesia, duration of treatment, side effects, and drop out were evaluated for each drug. Twenty-four percent of the patients still benefitted from treatment at the fourth week of study, even if high drug dosages were not used. Pentazocine did not show an evident analgesic effect during the first 2 wk of treatment. The other opioids were found to be valid therapeutic instruments for chronic cancer pain control in a limited number of patients.

Original languageEnglish
Pages (from-to)423-427
Number of pages5
JournalJournal of Pain and Symptom Management
Volume6
Issue number7
DOIs
Publication statusPublished - 1991

Keywords

  • dosage
  • duration of treatment
  • Opioids
  • pain relief
  • side effects

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology
  • Neurology
  • Nursing(all)

Fingerprint Dive into the research topics of 'A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain'. Together they form a unique fingerprint.

  • Cite this